At the FSED meeting, investigators highlight SGLT2 inhibitors, finerenone, and GLP-1 or GIP agents as promising strategies to slow kidney decline and cut CV risk in type 1 diabetes.
Medscape News Europe
Source link : https://www.medscape.com/viewarticle/new-trials-offer-hope-type-1-diabetic-kidney-disease-2026a1000eqz?src=rss
Author :
Publish date : 2026-05-07 13:02:00
Copyright for syndicated content belongs to the linked Source.
